Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1b/2a, Open-label, Randomized, Safety, Tolerability, Dose Finding, Pharmacokinetic/Pharmacodynamic, and Preliminary Efficacy Study of Subcutaneous Hanferon in Combination With Ribavirin in Treatment-naive Subjects With Genotype 1 Hepatitis C.

Next Previous
Trial Profile

A Phase 1b/2a, Open-label, Randomized, Safety, Tolerability, Dose Finding, Pharmacokinetic/Pharmacodynamic, and Preliminary Efficacy Study of Subcutaneous Hanferon in Combination With Ribavirin in Treatment-naive Subjects With Genotype 1 Hepatitis C.

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 14 Jan 2020

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Interferon alpha-2b (Primary) ; Peginterferon alfa-2a (Primary) ; Ribavirin (Primary)
  • Indications Hepatitis C
  • Focus Therapeutic Use
  • Sponsors HanAll Biopharma

    • Most Recent Events

    • 22 Apr 2014 Status changed from active, no longer recruiting to completed according to ClinicalTrial.gov record.
    • 19 Jun 2012 Phase IIa testing is ongoing, according to a HanAll BioPharma media release.
    • 02 Apr 2012 Planned End Date changed from 1 Jan 2012 to 1 Jun 2012 as reported by ClinicalTrials.gov.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top